Cited by 133Histone Deacetylase Inhibitors ResearchAlzheimer's disease research and treatmentsCancer, Lipids, and Metabolism

Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor protein

Open access
Venkataramani, Vivek, Rossner, Christian, Iffland, Lara, Schweyer, Stefan, Tamboli, Irfan Y., Walter, Jochen, Wirths, Oliver, Bayer, Thomas A.·2010·Journal of Biological Chemistry

Abstract

The beta-amyloid precursor protein (APP) represents a type I transmembrane glycoprotein that is ubiquitously expressed. In the brain, it is a key player in the molecular pathogenesis of Alzheimer disease. Its physiological function is however less well understood. Previous studies showed that APP is up-regulated in prostate, colon, pancreatic tumor, and oral squamous cell carcinoma. In this study, we show that APP has an essential role in growth control of pancreatic and colon cancer. Abundant APP staining was found in human pancreatic adenocarcinoma and colon cancer tissue. Interestingly, treating pancreatic and colon cancer cells with valproic acid (VPA, 2-propylpentanoic acid), a known histone deacetylase (HDAC) inhibitor, leads to up-regulation of GRP78, an endoplasmic reticulum chaperone immunoglobulin-binding protein. GRP78 is involved in APP maturation and inhibition of tumor cell growth by down-regulation of APP and secreted soluble APPalpha. Trichostatin A, a pan-HDAC inhibitor, also lowered APP and increased GRP78 levels. In contrast, treating cells with valpromide, a VPA derivative lacking HDAC inhibitory properties, had no effect on APP levels. VPA did not modify the level of epidermal growth factor receptor, another type I transmembrane protein, and APLP2, a member of the APP family, demonstrating the specificity of the VPA effect on APP. Small interfering RNA-mediated knockdown of APP also resulted in significantly decreased cell growth. Based on these observations, the data suggest that APP down-regulation via HDAC inhibition provides a novel mechanism for pancreatic and colon cancer therapy.

Integrity signals

Registry

Crossref · 10.1074/jbc.m109.057836

Cites

90 of 90 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • TSA and SAHA do not directly inhibit cGAS-STING signaling or p38/mTOR phosphorylation, but instead restore OXPHOS gene expression and reduce mitochondrial ROS, thereby suppressing CCF and SASP.

    “TSA and SAHA, for example, do not directly inhibit cGAS–STING signaling or p38/mTOR phosphorylation, but instead restore OXPHOS gene expression and reduce mitochondrial ROS, thereby suppressing CCF and SASP (Vizioli et al., 2020; Khan and La Thangue, 2012; Venkataramani et al., 2010).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Venkataramani, V., Rossner, C., Iffland, L., Schweyer, S., Tamboli, I. Y., Walter, J., Wirths, O., & Bayer, T. A.
Affiliations
  • University of Göttingen (DE)
  • University of Bonn (DE)
Corresponding author
Bayer, Thomas A.
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
2010-04
Volume
285
Issue
14
Pages
10678-10689
ISSN
0021-9258 (ISSN-L)
OpenAlex
W2160421126
Cited by
133
References
90
Citations by year
2026: 2 · 2025: 3 · 2024: 3 · 2023: 2 · 2022: 8 · 2021: 4 · 2020: 10 · 2019: 8 · 2018: 6 · 2017: 6 · 2016: 8 · 2015: 9 · 2014: 13 · 2013: 21 · 2012: 12
FWCI
6.64
Type
journal article
Language
en
Open access
Locations
  • Journal of Biological Chemistry (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
valproic acid, histone deacetylase inhibitors, amyloid precursor protein, pancreatic ductal adenocarcinoma, colon cancer, GRP78, endoplasmic reticulum chaperone, soluble APP alpha, trichostatin A, valpromide, tumor cell proliferation, epidermal growth factor receptor, APLP2, Alzheimer's disease
MeSH terms
Endoplasmic Reticulum Chaperone BiP, Anticonvulsants, Colonic Neoplasms, Humans, Immunoenzyme Techniques, Pancreatic Neoplasms, Receptors, Cell Surface, Tumor Cells, Cultured, Valproic Acid, Down-Regulation, Amyloid beta-Protein Precursor, RNA, Small Interfering, Cell Proliferation, Histone Deacetylase Inhibitors, Protease Nexins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review